Jazz Pharmaceuticals secured accelerated FDA approval for dordaviprone (Modeyso), the first systemic treatment for recurrent H3 K27M-mutant diffuse midline glioma, a rare and aggressive brain tumor affecting children. The oral imipridone compound was acquired from Jazz’s earlier purchase of Chimerix in a $935 million deal. This milestone fills a significant unmet need for pediatric neuro-oncology by offering the first approved targeted therapy for this devastating disease.